XTL Sets Dec 28 Vote on $1M Related-Party Placement, New CEO and Psyga Name Change
XTLB is trading near its 52-week low of $1.37 (0.0% above the low) on light trading volume (0.3× avg).
Summary
XTL scheduled a December 28 shareholder meeting to approve a $1M private placement at $1.30 per ADS — with a 43.80% director as buyer — plus a new CEO, a name change to Psyga Ltd. and a new external director.
Key Events · Financing and Capital Events · XTLB
-
Related-Party Placement Up to $1M
Up to 769,230 ADSs (307,692,000 ordinary shares) at US$1.30 per ADS, with director Alexander Rabinovich, who holds approximately 43.80% of ordinary shares, among the investors. No placement agent is involved.
-
Warrant Reset Adds Dilution
Because the US$1.30 price is below US$2.70 per ADS, the deal is expected to trigger issuance of up to 555,556 Series C warrants and a reduction of the Series A warrant exercise price from the June 2026 private placement.
-
New CEO From January 2027
Yaron Kopel becomes CEO effective January 1, 2027, replacing Noam Band, on a NIS 60,000 monthly fee plus up to 550,000 ADS options at US$2.30 per ADS; several terms exceed the company's compensation policy.
-
Name Change to Psyga Ltd.
Board approved renaming the company Psyga Ltd. to reflect psychedelic medicine as its core business following the June 30, 2026 Psyga Bio acquisition.
Analysis · XTLB · Life Sciences
The December 28 shareholder vote will decide a $1M private placement priced at $1.30 per ADS, and Chairman Alexander Rabinovich — already holding about 43.80% — is among the buyers. That price sits below $2.70, so the deal also triggers up to 555,556 new Series C warrants and a cut to the Series A warrant strike, extending dilution beyond the placement itself. The same meeting installs Yaron Kopel as CEO from January 1, 2027 and renames the company Psyga Ltd., formalizing the pivot to psychedelic medicine after the June Psyga Bio acquisition. Approval is not guaranteed, and the company says it may not close the placement at all.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XTLB was trading at $1.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $1.37 to $5.64. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.